Mithra Pharmaceuticals SA

LSE:0R91 Stock Report

Market Cap: €14.9m

Mithra Pharmaceuticals Future Growth

Future criteria checks 5/6

Mithra Pharmaceuticals is forecast to grow earnings and revenue by 105.1% and 35.5% per annum respectively.

Key information

105.1%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.8%
Revenue growth rate35.5%
Future return on equityn/a
Analyst coverage

Low

Last updated09 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0R91 - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202613744N/AN/A1
12/31/202556-950602
12/31/202444-55-26-161
12/31/202340-174-2-2N/A
9/30/202351-126-15-6N/A
6/30/202363-79-28-9N/A
3/31/202365-69-55-33N/A
12/31/202267-60-82-57N/A
9/30/202244-76-92-68N/A
6/30/202222-93-102-78N/A
3/31/202222-105-100-78N/A
12/31/202123-117-98-77N/A
9/30/202121-115-94-75N/A
6/30/202119-113-91-73N/A
3/31/202114-103-94-77N/A
12/31/20209-92-96-80N/A
9/30/202044-31-85-70N/A
6/30/20207929-73-59N/A
3/31/2020881-68-53N/A
12/31/201997-27-62-47N/A
9/30/201984-54-42-28N/A
6/30/201971-82-21-5N/A
3/31/201964-55-14-1N/A
12/31/201858-28-74N/A
9/30/201846-41-23-9N/A
6/30/201833-53-40-25N/A
3/31/201833-46-44-28N/A
12/31/201732-38-47-31N/A
9/30/201726-37N/A-32N/A
6/30/201720-36N/A-32N/A
3/31/201721-36N/A-28N/A
12/31/201622-35N/A-23N/A
9/30/201621-29N/A-23N/A
6/30/201620-23N/A-22N/A
3/31/201620-16N/A-20N/A
12/31/201520-10N/A-18N/A
9/30/201519-9N/A-15N/A
6/30/201518-8N/A-12N/A
3/31/201519-5N/A-6N/A
12/31/201419-3N/A-1N/A
12/31/201318-2N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0R91 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: 0R91 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 0R91 is expected to become profitable in the next 3 years.

Revenue vs Market: 0R91's revenue (35.5% per year) is forecast to grow faster than the UK market (3.4% per year).

High Growth Revenue: 0R91's revenue (35.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0R91's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.